

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Evaluation

### Equality impact assessment – Scoping

#### Daprodustat for treating anaemia in adults with chronic kidney disease ID3987

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The company stated “The draft scope excluded the population who are not able to take ESAs. GSK’s target population for daprodustat promotes equality by widening the population with anaemia of CKD who would be eligible for treatment”

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

This view was raised in scope consultation; however, it is not considered an equality issue as the population does not exclude those who could not take ESAs. N.B. the scope was updated after consultation to include a comparator for people who cannot take ESAs.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

N/A

Health Technology Evaluation: Scoping

Equality impact assessment for the Health Technology Evaluation of Daprodustat for treating anaemia in adults with chronic kidney disease ID3987

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
--

N/A
-----

**Approved by Associate Director (name):** Henry Edwards

**Date:** 08/06/2022